



NDA 215515/S-002

## SUPPLEMENT APPROVAL

Alnylam Pharmaceuticals Inc.  
Attention: Bridget Rothwell, PharmD  
Associate Director, Regulatory Affairs  
300 Third Street  
Cambridge, MA 02142

Dear Dr. Rothwell:

Please refer to your supplemental new drug application (sNDA) dated August 26, 2022, received August 26, 2022, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Amvuttra (vutrisiran) injection.

This Prior Approval sNDA provides for changes to subsection 6.1 (Clinical Trials Experience) and subsection 13.1 (Carcinogenesis, Mutagenesis, Impairment of Fertility) of the prescribing information for Amvuttra based on safety data from study ALN-TTRSC02-002 and data from the final study report for the two-year carcinogenicity study of vutrisiran in rats.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **FULFILLMENT OF POSTMARKETING REQUIREMENT**

We have received your submission dated August 26, 2022, containing the final report for the following postmarketing requirement listed in the June 13, 2022, approval letter.

4288-1 A two-year carcinogenicity study of vutrisiran in rat.

Final Protocol Submission: 03/2022

Study Completion: 09/2021

Final Report Submission: 08/2022

We have reviewed your submission and conclude that the above requirement was fulfilled.

We remind you that there are postmarketing requirements listed in the June 13, 2022, approval letter that are still open.

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

## **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Annie Nguyen, Regulatory Project Manager at [Anhthu.Nguyen@fda.hhs.gov](mailto:Anhthu.Nguyen@fda.hhs.gov) or at (240) 402-4460.

Sincerely,

*{See appended electronic signature page}*

Teresa Buracchio, MD  
Director  
Division of Neurology 1  
Office of Neuroscience  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

TERESA J BURACCHIO  
02/16/2023 03:02:17 PM